Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Neoplasms 46Squamous Cell Carcinoma of Head and Neck 45Head and Neck Neoplasms 35Lung Neoplasms 34Uterine Cervical Neoplasms 27Neoplasm Metastasis 26Unspecified Adult Solid Tumor, Protocol Specific 24Stomach Neoplasms 24Ovarian Neoplasms 24Small Cell Lung Carcinoma 21Pancreatic Neoplasms 19Colorectal Neoplasms 18Cholangiocarcinoma 17Carcinoma, Squamous Cell 17Esophageal Neoplasms 16Breast Neoplasms 15Mesothelioma, Malignant 14Melanoma 13Urinary Bladder Neoplasms 12Mesothelioma 11Fallopian Tube Neoplasms 11Carcinoma, Ovarian Epithelial 11Sarcoma 9Gallbladder Neoplasms 9Esophageal Squamous Cell Carcinoma 9Biliary Tract Neoplasms 9Carcinoma 8Triple Negative Breast Neoplasms 7Recurrence 7

Interventions

trifluridine tipiracil drug combination 1tipiracil 1andecaliximab 1Trifluridine 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Irinotecan 1Indocyanine Green 1Gastrectomy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastric Adenocarcinoma × Cisplatin × Clear all
NCT02862535 2020-12-24

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Gilead Sciences

Phase 1 Terminated
36 enrolled 17 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡